This activity has been translated in clinical setting by reporting a better overall survival in IDH mutated AML patients treated with azacitidine/decitabine in combination with the BCL-2 inhibitor venetoclax [239,240]. The gene discussed is IDH1; the disease is acute myeloid leukemia.